Tuesday, August 04, 2020 12:41:13 PM
I bought 5000 shares today and plan to hold until phase III data out. If the drug is validated in phase III, one of the big pharms will buy out.
Recent ATHE News
- Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program • GlobeNewswire Inc. • 03/30/2026 11:25:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 10:03:09 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/19/2026 12:00:10 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/09/2026 12:00:00 PM
- Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit • GlobeNewswire Inc. • 03/09/2026 11:25:00 AM
- Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor • GlobeNewswire Inc. • 03/04/2026 12:25:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2026 11:03:24 AM
- Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments • GlobeNewswire Inc. • 03/02/2026 12:25:00 PM
- Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update • GlobeNewswire Inc. • 01/30/2026 12:25:00 PM
- Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026 • GlobeNewswire Inc. • 01/21/2026 12:25:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2025 11:35:16 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2025 11:29:32 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2025 11:23:07 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2025 11:13:30 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2025 11:38:48 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/12/2025 01:08:15 PM
- Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference • GlobeNewswire Inc. • 11/12/2025 12:25:00 PM
- Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System • GlobeNewswire Inc. • 11/10/2025 12:25:00 PM
- Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report • GlobeNewswire Inc. • 10/31/2025 11:25:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/31/2025 11:12:43 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/21/2025 10:51:14 AM
- Alterity Therapeutics Shares Edge Higher After Encouraging MSA Trial Results • IH Market News • 10/09/2025 02:38:49 PM
- Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders • GlobeNewswire Inc. • 10/09/2025 11:25:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/09/2025 10:33:24 AM
- Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders • GlobeNewswire Inc. • 10/02/2025 11:35:00 AM
